Relmada Therapeutics (RLMD) Proxy filing summary

Executive summary

• 2025 was a transformational year, marked by a strategic pivot after a failed lead program, disciplined expense management, and successful acquisition of two clinical-stage assets, NDV-01 and sepranolone, positioning the company for renewed value creation in 2026.

• Share price rebounded from $0.24 to $4.83, and cash reserves increased to $100 million after a successful $100 million financing, enabling robust clinical development plans.

• The company retained and strengthened its core team, notably adding a Chief Medical Officer for Urology, and maintained its NASDAQ listing through proactive investor engagement.

Voting matters and shareholder proposals

• Election of two Class II directors for three-year terms expiring in 2029.

• Ratification of CBIZ CPAs P.C. as independent auditor for fiscal year ending December 31, 2026.

• Approval to amend the 2021 Equity Incentive Plan, increasing shares available for issuance by 3 million.

• Approval to amend Articles of Incorporation to increase authorized common stock from 150,000,000 to 200,000,000 shares.

Board of directors and corporate governance

• Board consists of five members, with a majority deemed independent under Nasdaq rules.

• Leadership roles of Chairman and CEO are separated for effective oversight.

• Three standing committees: Audit, Compensation, and Nominating/Corporate Governance, all with independent members and reviewed charters.

• Board diversity is considered in director nominations, focusing on experience, skills, and background.